Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Cara Therapeutics	Olema Pharmaceuticals	Theravance Biopharma	Applied Molecular Transport	Aclaris Therapeutics
Symbol	NASDAQ:CARA	NASDAQ:OLMA	NASDAQ:TBPH	NASDAQ:AMTI	NASDAQ:ACRS
Price Information
Current Price	$12.41	$21.95	$19.18	$43.78	$23.34
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.8	1.6	1.6	2.0	0.8
Analysis Score	3.5	3.5	3.5	3.5	0.0
Community Score	3.1	4.3	2.4	3.6	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	1.7	2.5	0.8
Earnings & Valuation Score	0.6	0.0	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$32.00	$60.67	$33.14	$68.75	N/A
% Upside from Price Target	157.86% upside	176.39% upside	72.80% upside	57.04% upside	N/A
Trade Information
Market Cap	$628.53 million	$867.67 million	$1.29 billion	$1.62 billion	$1.20 billion
Beta	1.7	N/A	0.94	N/A	1.2
Average Volume	1,045,991	150,375	332,764	231,097	2,286,868
Sales & Book Value
Annual Revenue	$19.89 million	N/A	$73.41 million	N/A	$4.23 million
Price / Sales	31.22	N/A	17.04	N/A	287.39
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.66 per share	N/A	($3.94) per share	N/A	$1.69 per share
Price / Book	2.66	N/A	-4.87	N/A	13.81
Profitability
Net Income	$-106,370,000.00	N/A	$-236,460,000.00	$-28,040,000.00	$-161,350,000.00
EPS	($2.49)	N/A	($4.25)	N/A	($2.25)
Trailing P/E Ratio	N/A	0.00	N/A	0.00	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-360.35%	N/A	-345.16%	N/A	-941.07%
Return on Equity (ROE)	-64.36%	N/A	N/A	N/A	-104.00%
Return on Assets (ROA)	-53.22%	N/A	-51.60%	N/A	-64.47%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	0.26%
Current Ratio	8.00%	N/A	4.32%	19.39%	4.54%
Quick Ratio	8.00%	N/A	4.32%	19.39%	4.54%
Ownership Information
Institutional Ownership Percentage	67.01%	N/A	80.41%	51.99%	59.10%
Insider Ownership Percentage	5.70%	N/A	5.90%	N/A	8.20%
Miscellaneous
Employees	80	36	359	80	57
Shares Outstanding	50.04 million	40.17 million	65.22 million	35.25 million	52.09 million
Next Earnings Date	5/10/2021 (Confirmed)	6/16/2021 (Estimated)	8/5/2021 (Estimated)	6/18/2021 (Estimated)	8/6/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Aclaris Therapeutics (NASDAQ:ACRS) Issues Earnings Results americanbankingnews.com - May 8 at 12:08 PM
	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com - May 7 at 12:44 PM
	Aclaris: Q1 Earnings Snapshot seattlepi.com - May 7 at 7:44 AM
	Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update finance.yahoo.com - May 7 at 7:44 AM
	Aclaris Therapeutics, Inc. Forecasted to Earn FY2022 Earnings of ($1.37) Per Share (NASDAQ:ACRS) americanbankingnews.com - May 6 at 11:42 AM
	Kamil Ali-Jackson Sells 15,000 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock americanbankingnews.com - May 5 at 11:08 PM
	Insider Selling: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Insider Sells 15,000 Shares of Stock americanbankingnews.com - May 5 at 11:08 PM
	Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Metrics You Need to Know Right Now stocksregister.com - May 1 at 2:48 PM
	Aclaris Therapeutics (NASDAQ:ACRS) Rating Lowered to Sell at Zacks Investment Research marketbeat.com - April 27 at 4:51 PM
	HC Wainwright Initiates Coverage on Aclaris Therapeutics (NASDAQ:ACRS) americanbankingnews.com - April 27 at 9:12 AM
	Aclaris Therapeutics Inc (ACRS) President and CEO Neal Walker Sold $805,200 of Shares uk.finance.yahoo.com - April 27 at 6:57 AM
	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) CFO Frank Ruffo Sells 30,000 Shares americanbankingnews.com - April 26 at 10:50 PM
	Aclaris Therapeutics (NASDAQ:ACRS) Trading Down 4.1% americanbankingnews.com - April 26 at 1:46 PM
	Is ACRS Stock A Buy or Sell? finance.yahoo.com - April 26 at 7:23 AM
	Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $26.46 americanbankingnews.com - April 21 at 10:38 AM
	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 41.5% in March americanbankingnews.com - April 18 at 1:14 AM
	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) share price rebounds 96.18% from the lows – but can it keep going? marketingsentinel.com - April 17 at 6:00 PM
	Aclaris Therapeutics Stock Appears To Be Significantly Overvalued finance.yahoo.com - April 1 at 8:23 AM
	Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for ... apnews.com - March 16 at 9:44 AM
	Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis finance.yahoo.com - March 15 at 8:29 AM
	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a ... apnews.com - February 26 at 9:58 AM
	Aclaris: 4Q Earnings Snapshot \| Raleigh News & Observer newsobserver.com - February 25 at 1:29 PM
	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update finance.yahoo.com - February 25 at 8:29 AM
	Aclaris Therapeutics to Participate in Upcoming Investor Conferences finance.yahoo.com - February 22 at 9:00 AM
	Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference finance.yahoo.com - February 10 at 9:06 AM
	Gaining Ground After A Tough Couple Of Weeks finance.yahoo.com - January 25 at 7:34 PM

Date	Company	Brokerage	Action
5/5/2021	Cara Therapeutics	Needham & Company LLC	Lower Price Target
9/8/2020	Cara Therapeutics	Canaccord Genuity	Reiterated Rating
5/19/2020	Cara Therapeutics	Cantor Fitzgerald	Boost Price Target
4/21/2020	Cara Therapeutics	HC Wainwright	Boost Price Target
7/30/2019	Cara Therapeutics	Piper Jaffray Companies	Boost Price Target
5/29/2019	Cara Therapeutics	Laidlaw	Boost Price Target
2/6/2019	Cara Therapeutics	Jefferies Financial Group	Initiated Coverage
1/15/2019	Cara Therapeutics	Bank of America	Initiated Coverage
12/14/2020	Olema Pharmaceuticals	JPMorgan Chase & Co.	Initiated Coverage
12/14/2020	Olema Pharmaceuticals	Cowen	Initiated Coverage
5/5/2021	Theravance Biopharma	SVB Leerink	Lower Price Target
3/8/2021	Theravance Biopharma	Morgan Stanley	Lower Price Target
11/23/2020	Theravance Biopharma	Evercore ISI	Reiterated Rating
8/7/2020	Theravance Biopharma	Piper Sandler	Lower Price Target
11/6/2019	Theravance Biopharma	Robert W. Baird	Upgrade
3/23/2021	Applied Molecular Transport	JMP Securities	Initiated Coverage
10/11/2019	Aclaris Therapeutics	William Blair	Reiterated Rating

(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources